Teriparatide and calcitonin are both used in bone health, but they take opposite approaches. Teriparatide is anabolic — it actively builds new bone. Calcitonin is antiresorptive — it slows the breakdown of bone. Both are FDA-approved, but teriparatide is a far more potent, modern osteoporosis therapy, while calcitonin is an older, weaker option.
At a glance
| Teriparatide | Calcitonin | |
|---|---|---|
| Class | Recombinant PTH (1–34) — anabolic | Hormone — antiresorptive |
| Brand name | Forteo | Miacalcin (and others) |
| FDA status | Approved | Approved |
| What it does | Builds new bone | Slows bone breakdown |
| Dosing | Once-daily injection | Nasal spray or injection |
| Relative strength | Potent anabolic agent | Weaker, older option |
The bottom line
Bottom line: They sit on opposite sides of bone metabolism. Teriparatide actively builds bone and is a potent agent reserved for higher-risk osteoporosis; calcitonin merely slows bone loss and is a milder, older choice now used less often. Both are approved prescription medicines, but they are not equivalent in strength or role.
Frequently asked questions
What's the difference between teriparatide and calcitonin?
Teriparatide is an anabolic drug that actively builds new bone, while calcitonin is an antiresorptive hormone that slows bone breakdown. Teriparatide is a potent, modern osteoporosis agent; calcitonin is a weaker, older option.
Which is stronger for osteoporosis?
Teriparatide is considerably more potent because it builds new bone, and it is typically reserved for people at high fracture risk. Calcitonin only slows bone loss and is now used less frequently.
Are both FDA-approved?
Yes. Teriparatide (Forteo) and calcitonin (Miacalcin and others) are both FDA-approved, but for different roles in bone health and with different strengths.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001. Peer-reviewed study
- Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human PTH(1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003. Peer-reviewed study
- Leder BZ, Tsai JN, Uihlein AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015. Peer-reviewed study
- Li M, Ge Z, Zhang B, et al. Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos. 2024. Peer-reviewed study
- Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther. 2004. Peer-reviewed study
- Yuan F, Peng W, Yang C, et al. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis. Int J Surg. 2019. Peer-reviewed study
- Muñoz-Torres M, Alonso G, Raya MP. Calcitonin therapy in osteoporosis. Treat Endocrinol. 2004. Peer-reviewed study
- Ringe JD. [Calcitonin in the prevention and therapy of osteoporosis]. Ther Umsch. 1991. Peer-reviewed study
- Silverman SL. Calcitonin. Endocrinol Metab Clin North Am. 2003. Peer-reviewed study
- Silverman SL. Calcitonin. Am J Med Sci. 1997. Peer-reviewed study
- Neumüller J, Lang-Illievich K, Brenna CTA, et al. Calcitonin in the Treatment of Phantom Limb Pain: A Systematic Review. CNS Drugs. 2023. Peer-reviewed study
- Reginster JY. [Calcitonin]. Rev Med Liege. 1996. Peer-reviewed study